Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of advanced NSCLC. In late 2018, Tecentriq (Roche/Genentech/Chugai) was the second immune checkpoint inhibitor to enter the coveted first-line metastatic setting, after Keytruda (Merck & Co.). Competition is set to intensify further over the forecast period as multiple combination therapies based on immune checkpoint inhibitors gain approval and enter the clinic. In addition, novel biomarker-driven therapies such as next-generation EGFR and ALK inhibitors are vying for a share of the increasingly crowded and competitive NSCLC market.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.
Khurram Nawaz is a director in the oncology team at Decision Resources Group. Mr. Nawaz manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. He also provides sales and client support on syndicated and custom oncology products, translating domain knowledge into actionable insights. Previously, Mr. Nawaz was a principal analyst in the oncology team at Decision Resources Group, where he developed considerable expertise in forecasting complex oncology and hemato-oncology drug markets, and conducted detailed primary research with physicians and payers across multiple geographies. He has in-depth expertise in immuno-oncology, non-small-cell lung cancer, prostate cancer, multiple myeloma, and other solid and hematological malignancies. Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders. He holds a in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a in life sciences from the Pierre and Marie Curie–Paris VI University.